P. Leconte

Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer

Background The PD-1 inhibitor pembrolizumab has shown robust clinical activity in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H)...

M. Gumus ;

J. Bae Ahn ;

L. Wyrwicz ;

M. Kwiatkowski ;

J. Kim ;

S. Yalcin ;

M. Sendur ;

A. Odeleye-Ajakaye ;

P. Leconte ;

T. Andre ;

T. Kim ;

D. Fogelman ;

C. Sposetti ;

06/27/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

P. Leconte

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products